Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
Accession Number
DB10794
Description

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) is combined with Acetylsalicylic acid.
AdalimumabThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Altretamine.
Aminosalicylic acidThe risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) is combined with Aminosalicylic acid.
AmsacrineThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Active Moieties
NameKindUNIICASInChI Key
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)hemagglutinin166D8OWM7BNot AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
FluadInfluenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSeqirus, Inc.2015-11-242016-11-23US flag
FluadInfluenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSeqirus Inc.2017-07-012018-06-30US flag
Fluarix 2011/2012Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2011-07-012011-07-01US flag
Fluarix Quadrivalent 2013/2014Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Christchurch/16/2010 NIB-74XP (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2013-07-012013-05-31US flag
Fluarix Quadrivalent 2014/2015Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Christchurch/16/2010 NIB-74XP (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2014-07-012014-06-27US flag
Fluarix Quadrivalent 2015/2016Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Christchurch/16/2010 NIB-74XP (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2015-07-012015-06-30US flag
Fluarix Quadrivalent 2016/2017Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Christchurch/16/2010 NIB-74XP (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2016-07-012016-05-31US flag
Fluarix Quadrivalent 2017/2018Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2017-07-072018-06-30US flag
FluzoneInfluenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Brisbane/59/2007 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Uruguay/716/2007(H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2009-07-012010-06-30US flag
FluzoneInfluenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularPhysicians Total Care, Inc.2010-09-212011-06-30US flag

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
W45Z4CJE2J
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingBasic ScienceFlu caused by Influenza3
4Active Not RecruitingBasic ScienceFlu caused by Influenza / Healthy Adults / Hepatitis A / Salmonella Typhi Infection1
4Active Not RecruitingPreventionFlu caused by Influenza1
4CompletedBasic ScienceCytomegalovirus (CMV) Infection / Flu caused by Influenza1
4CompletedBasic ScienceFlu caused by Influenza12
4CompletedBasic ScienceFlu Vaccine1
4CompletedBasic ScienceImmune Response to Influenza Vaccine / Influenza A Virus Infection / Influenza B Virus Infection1
4CompletedBasic ScienceMELAS Syndrome1
4CompletedBasic ScienceRheumatoid Arthritis1
4CompletedOtherFlu caused by Influenza1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionIntramuscular
Injection, suspensionIntramuscular
Injection, suspensionIntradermal
KitTopical
Injection, suspension
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 20:04 / Updated on June 12, 2020 16:53